Sandoz

Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Fierce Pharma
Fri, 12/8/17 - 10:41 am
Novartis
Neulasta
biosimilars
Amgen
Sandoz
FDA
Novartis looks at offloading its generic pills business in U.S. as market continues to decline
Fierce Pharma
Mon, 12/4/17 - 11:39 am
Novartis
generics
Sandoz
M&A
Amazon in talks with generic drugmakers including Mylan, Sandoz about pharma play: report
Fierce Pharma
Sun, 12/3/17 - 11:35 am
Amazon
generics
Sandoz
Mylan Labs
Sandoz head sees biosimilars as the light in the generics storm
Fierce Pharma
Thu, 11/30/17 - 11:05 am
generics
biosimilars
Sandoz
Peter Goldschmidt
Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars
Endpoints
Wed, 10/25/17 - 10:59 am
Sandoz
Novartis
FDA
biosimilars
Novartis division closing Broomfield operations
Broomfield Enterprise, Colorado
Tue, 10/17/17 - 09:46 am
Novartis
drug manufacturing
Sandoz
generics
Lilly wards off another Alimta patent challenge, this time through IPR
Fierce Pharma
Fri, 10/6/17 - 11:42 am
Eli Lilly
Alimta
patents
IPR
lung cancer
Neptune
generics
Novartis
Sandoz
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Fri, 07/14/17 - 07:58 am
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Tue, 07/4/17 - 11:22 pm
Biogen
Tecfidera
generics
MS
multiple sclerosis
Novartis
Sandoz
Mylan Labs
Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Thu, 06/29/17 - 09:43 am
Novartis
biosimilars
Enbrel
Europe
Sandoz
Erelzi
Roche
Rituxan
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Endpoints
Mon, 06/19/17 - 03:16 pm
Novartis
biosimilars
Rituxan
Roche
Sandoz
Novartis pushes further into pain with Durect deal
BioPharma Dive
Tue, 05/9/17 - 10:45 pm
Novartis
Durect
Sandoz
biosimilars
generics
Posimir
R&D
The Demise of the BPCIA Patent Dance?
FDA Law Blog
Fri, 03/3/17 - 09:40 am
BPCIA
patents
Genentech
Amgen
Sandoz
Avastin
In Amgen-Sandoz SCOTUS case, biosim makers lambaste ruling's 6-month exclusivity gift
Fierce Pharma
Wed, 02/22/17 - 09:44 am
Amgen
Sandoz
Supreme Court
biosimilars
Amgen and the BPCIA Patent Dance – Redux
FDA Law Blog
Mon, 02/20/17 - 10:07 am
Amgen
patents
BPCIA
FDA
Sandoz
Neupogen
generics
Genentech
Avastin
Amgen Fight Over Copies of Biotech Drugs Gets High Court Review
Bloomberg
Sat, 01/14/17 - 03:35 pm
Amgen
Supreme Court
Neupogen
Novartis
Sandoz
biosimilars
Novartis donates $10M in generics to global relief
BioPharma Dive
Mon, 11/28/16 - 11:29 pm
Novartis
generics
philanthropy
Sandoz
Novartis May Be Too Generic
TheStreet.com
Fri, 10/21/16 - 11:39 am
Novartis
generics
patents
Sandoz
Generics creep in as Teva loses two Copaxone patents
BioPharma Dive
Fri, 08/26/16 - 09:55 am
Teva Pharmaceutical
Copaxone
patents
MS
multiple sclerosis
generics
Glatopa
Novartis
Sandoz
Sandoz Enbrel biosim cruises at FDA panel, endangering key Amgen sales
Fierce Pharma
Wed, 07/13/16 - 06:22 pm
Sandoz
Novartis
FDA
advisory panels
biosimilars
Enbrel
Amgen

Pages